Company research
Vir Biotechnology, Inc.
CIK 1706431Updated Sep 24, 2026
SecurityVIR · NASDAQ · equity
VIR price & chart
Loading TradingView…
NASDAQ:VIR on TradingView ↗About the company
VIR-5818, VIR-5500, VIR-5525 are investigational, clinical candidates currently being evaluated for the treatment of solid tumors. These assets leverage the PRO-XTEN™ masking technology with three different T-cell engagers (TCEs) targeting HER2, PSMA, and EGFR, respectively. TCEs are powerful anti-tumor agents that can direct the immune system, specifically T-cells, to destroy cancer cells. The PRO-XTEN™ masking technology is designed to keep the TCEs inactive (or masked) until they reach the tumor microenvironment, where tumor-specific proteases cleave off the mask and activate the TCEs, leading to killing of cancer cells. By driving the activity exclusively to the tumor microenvironment, we aim to circumvent the traditionally high toxicity associated with TCEs and increase their efficacy and tolerability. Additionally, the mask is designed to help drug candidates stay in the bloodstream longer in their inactive form, allowing them to better reach the site of action and potentially allowing less frequent dosing regimens for patients and clinicians.
In the news
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,002,823,000Source | 1,398,813,000Source | 1,919,060,000Source | 2,802,088,000Source |
| Property, Plant and Equipment, NetUSD | 55,620,000Source | 63,183,000Source | 96,018,000Source | 105,609,000Source |
| GoodwillUSD | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,850,000Source | 8,120,000Source | 22,565,000Source | 32,755,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 232,185,000Source | 222,947,000Source | 241,576,000Source | 848,631,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 0Source |
| Assets, CurrentUSD | 514,080,000Source | 1,042,458,000Source | 1,588,226,000Source | 2,519,077,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 45,143,000Source | 47,725,000Source | 52,549,000Source | 104,356,000Source |
| Operating Lease, Right-of-Use AssetUSD | 62,099,000Source | 59,680,000Source | 71,182,000Source | 82,557,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 237,547,000Source | 248,428,000Source | 328,824,000Source | 724,125,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 14,000Source | 14,000Source | 13,000Source | 13,000Source |
| Additional Paid in CapitalUSD | 1,965,090,000Source | 1,911,872,000Source | 1,828,862,000Source | 1,709,835,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,197,771,000Source | -759,784,000Source | -237,824,000Source | 377,237,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,057,000Source | -1,717,000Source | -815,000Source | -9,122,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | — | — | 2,077,963,000Source |
| Liabilities and EquityUSD | 1,002,823,000Source | 1,398,813,000Source | 1,919,060,000Source | 2,802,088,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 92,815,000Source | 119,662,000Source | 175,407,000Source | 511,029,000Source |
| Operating Lease, Liability, CurrentUSD | 8,798,000Source | 7,752,000Source | 12,867,000Source | 4,137,000Source |
| Accounts Payable, CurrentUSD | 9,803,000Source | 5,081,000Source | 6,334,000Source | 6,422,000Source |
| Operating Lease, Liability, NoncurrentUSD | 89,054,000Source | 90,139,000Source | 111,673,000Source | 123,837,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | 3,253,000Source |
| Other Liabilities, NoncurrentUSD | 21,578,000Source | 14,577,000Source | 14,258,000Source | 7,862,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,630,000,000Source | 2,400,000,000Source |
| Deferred Revenue, CurrentUSD | — | 12,648,000Source | 64,853,000Source | 15,517,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | 1,526,000Source | 53,207,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | 2,190,000Source | 3,253,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -437,987,000Source | -521,960,000Source | -615,117,000Source | 515,837,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 11,680,000Source | 14,559,000Source | 18,920,000Source | 6,251,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 49,072,000Source | 78,457,000Source | 111,316,000Source | 102,082,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | 6,513,000Source | 565,000Source | -770,038,000Source |
| Increase (Decrease) in Accounts PayableUSD | 4,997,000Source | -988,000Source | 732,000Source | 797,000Source |
| Deferred Income Tax Expense (Benefit)USD | 304,000Source | -2,949,000Source | -1,063,000Source | -15,186,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -391,781,000Source | -446,352,000Source | -778,785,000Source | 1,663,253,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 310,371,000Source | 499,367,000Source | 164,629,000Source | -1,193,461,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,832,000Source | 7,301,000Source | 21,573,000Source | 68,028,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 3,785,000Source | 4,388,000Source | 7,480,000Source | 34,761,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -361,000Source | -165,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -77,625,000Source | 57,403,000Source | -606,676,000Source | 504,553,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 241,070,000Source | 318,695,000Source | 261,292,000Source | 867,968,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 2,420,000Source | 786,000Source | 2,676,000Source | 252,030,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 49,072,000Source | 78,457,000Source | 111,316,000Source | 102,082,000Source |
| Amortization of Intangible AssetsUSD | — | — | 531,000Source | 532,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,630,000,000Source | 2,400,000,000Source |
| DepreciationUSD | 11,400,000Source | 14,200,000Source | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | 0Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 1,729,000Source | -5,528,000Source | -21,888,000Source | -111,140,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | 0Source | 0Source |
| GoodwillUSD | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 14,550,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 9,658,000Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 217,000Source | -1,145,000Source | -13,077,000Source | 238,443,000Source |
| Investment Income, InterestUSD | 40,238,000Source | 71,809,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -437,987,000Source | -521,960,000Source | -615,117,000Source | 515,837,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 0Source | 0Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -615,061,000Source | — |
| Nonoperating Income (Expense)USD | 41,558,000Source | 64,060,000Source | 56,111,000Source | -78,788,000Source |
| Other Nonoperating Income (Expense)USD | -409,000Source | -2,221,000Source | -8,991,000Source | 4,260,000Source |
| Payments to Acquire InvestmentsUSD | 886,334,000Source | 1,235,339,000Source | 2,016,189,000Source | 1,476,965,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | 100,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 1,349,000Source | 790,000Source | 3,484,000Source | 4,534,000Source |
| Restructuring Costs and Asset Impairment ChargesUSD | -182,000Source | 34,995,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 68,556,000Source | 74,205,000Source | 86,180,000Source | 1,615,797,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 92,074,000Source | 119,031,000Source | 178,049,000Source | 161,762,000Source |
| Operating Income (Loss)USD | -479,328,000Source | -587,165,000Source | -684,305,000Source | 833,068,000Source |
| Other Nonoperating Income (Expense)USD | -409,000Source | -2,221,000Source | -8,991,000Source | 4,260,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -437,770,000Source | -523,105,000Source | -628,194,000Source | 754,280,000Source |
| Income Tax Expense (Benefit)USD | 217,000Source | -1,145,000Source | -13,077,000Source | 238,443,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -437,987,000Source | -521,960,000Source | -615,117,000Source | 515,837,000Source |
| Earnings Per Share, BasicUSD per share | -3.16Source | -3.83Source | -4.59Source | 3.89Source |
| Earnings Per Share, DilutedUSD per share | -3.16Source | -3.83Source | -4.59Source | 3.83Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 138,520,419Source | 136,246,865Source | 134,130,924Source | 132,606,767Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 138,520,419Source | 136,246,865Source | 134,130,924Source | 134,810,908Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 531,000Source | 532,000Source |
| Costs and ExpensesUSD | 547,884,000Source | 661,370,000Source | 770,485,000Source | 782,729,000Source |
| Current Income Tax Expense (Benefit)USD | -87,000Source | 1,804,000Source | -12,014,000Source | 253,629,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -448,370,000Source | -499,680,000Source | -608,134,000Source | 692,445,000Source |
| Investment Income, InterestUSD | 40,238,000Source | 71,809,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -615,061,000Source | — |
| Nonoperating Income (Expense)USD | 41,558,000Source | 64,060,000Source | 56,111,000Source | -78,788,000Source |
| Research and Development ExpenseUSD | 455,966,000Source | 506,499,000Source | 589,671,000Source | 474,648,000Source |
Filing attachments
d887412dex991.htm · 8-K · 2025-01-08
EX-99.1 3 d887412dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage observed in 50% (10/20) of participants with various HER2-…
Read attachment ↗